Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides

Annals of the Rheumatic Diseases

Volumn 68, Issue 10, 2009, Pages 1564-1571

  Terrier, B ^a   Saadoun, D ^a,b   Sene D ^a   Ghillani, P ^a   Amoura, Z ^a   Deray, G ^a   Fautrel, B ^a   Piette, J C ^a,b   Cacoub, P ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; ENZYME ANTIBODY; METHYLPREDNISOLONE; MYELOPEROXIDASE ANTIBODY; PREDNISONE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CHURG STRAUSS SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; COURSE EVALUATION; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MALE; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; PRIORITY JOURNAL; RELAPSE; REMISSION; SCORING SYSTEM; WEGENER GRANULOMATOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; VASCULITIS; YOUNG ADULT;

EID: 70349395712     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.094714     Document Type: Article

References (57)

1. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-418
2. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521-1537
3. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421-430 (Pubitemid 29136088)
4. Falk RJ, Jennette JC. Thoughts about the classification of small vessel vasculitis. J Nephrol 2004;17(Suppl 8):S3-9.
5. Wiik A. Rational use of ANCA in the diagnosis of vasculitis. Rheumatology (Oxford) 2002;41:481-483 (Pubitemid 34567175)
6. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol 2006;17:1235-1242 (Pubitemid 43673403)
7. Schlieben DJ, Korbet SM, Kimura RE, et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005;45:758-761
8. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004;93:398-401.
9. Williams JM, Ben-Smith A, Hewins P, et al. Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J Am Soc Nephrol 2003;14:661-669
10. Porges AJ, Redecha PB, Kimberly WT, et al. Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 1994;153:1271-1280 (Pubitemid 24228519)
11. Charles LA, Caldas ML, Falk RJ, et al. Antibodies against granule proteins activate neutrophils in vitro. J Leukoc Biol 1991;50:539-546
12. Falk RJ, Terrell RS, Charles LA, et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990;87:4115-4119
13. Williams JM, Kamesh L, Savage CO. Translating basic science into patient therapy for ANCA-associated small vessel vasculitis. Clin Sci (Lond) 2005;108:101-112 (Pubitemid 40175403)
14. Kettritz R, Jennette JC, Falk RJ. Crosslinking of ANCA-antigens stimulates superoxide release by human neutrophils. J Am Soc Nephrol 1997;8:386-394 (Pubitemid 127454174)
15. Mulder AH, Heeringa P, Brouwer E, et al. Activation of granulocytes by antineutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol 1994;98:270-278 (Pubitemid 24336825)
16. Radford DJ, Luu NT, Hewins P, et al. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 2001;44:2851-2861 (Pubitemid 34016205)
17. Radford DJ, Savage CO, Nash GB. Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 2000;43:1337-1345
18. Savage CO, Pottinger BE, Gaskin G, et al. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 1992;141:335-342
19. Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992;41:375-383
20. Rarok AA, Limburg PC, Kallenberg CG. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leukoc Biol 2003;74:3-15.
21. Huugen D, Xiao H, van Esch A, et al. Aggravation of anti-myeloperoxidase antibodyinduced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol 2005;167:47-58. (Pubitemid 40884769)
22. Xiao H, Heeringa P, Liu Z, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005;167:39-45. (Pubitemid 40884768)
23. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110:955-963
24. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005;106:2050-2058 (Pubitemid 41291719)
25. Pfister H, Ollert M, Frohlich LF, et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004;104:1411-1418 (Pubitemid 39166519)
26. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007;170:52-64. (Pubitemid 47339189)
27. Guilpain P, Servettaz A, Goulvestre C, et al. Pathogenic effects of antimyeloperoxidase antibodies in patients with microscopic polyangiitis. Arthritis Rheum 2007;56:2455-2463 (Pubitemid 47173595)
28. Stegeman CA, Tervaert JW, Kallenberg CG. Anti-neutrophil cytoplasmic antibodies: tools for diagnosis and follow-up in systemic vasculitis. Ann Med Interne (Paris) 1994;145:523-532
29. Girard T, Mahr A, Noel LH, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. Rheumatology (Oxford) 2001;40:147-151 (Pubitemid 32229633)
30. Gaskin G, Savage CO, Ryan JJ, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991;6:689-694
31. De'Oliviera J, Gaskin G, Dash A, et al. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995;25:380-389
32. Kyndt X, Reumaux D, Bridoux F, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999;106:527-533 (Pubitemid 29231103)
33. Jayne DR, Gaskin G, Pusey CD, et al. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995;88:127-133
34. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985;1:425-429 (Pubitemid 15173133)
35. Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43:2025-2033
36. Tervaert JW, Huitema MG, Hene RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-711
37. Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149:2461-2465 (Pubitemid 19283202)
38. Sanders JS, Huitma MG, Kallenberg CG, et al. Prediction of relapses in PR3-ANCAassociated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006;45:724-729
39. Stegeman CA. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCAassociated small-vessel vasculitis. Nephrol Dial Transplant 2002;17:2077-2080
40. Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007;147:611-619 (Pubitemid 351664480)
41. Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993;36:365-371 (Pubitemid 23090604)
42. Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis. Ann Intern Med 1995;123:925-932
43. Pettersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992;37:219-228
44. Ara J, Mirapeix E, Rodriguez R, et al. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999;14:1667-1672 (Pubitemid 29313043)
45. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-1093
46. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-192
47. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-1107
48. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-1100
49. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-227 (Pubitemid 46226058)
50. Luqmani RA, Bacon PA, Moots RJ, et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. Q J Med 1994;87:671-678
51. de Groot K, Gross WL, Herlyn K, et al. Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001;55:31-38 (Pubitemid 32041780)
52. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-617 (Pubitemid 46707128)
53. Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005;143:621-631 (Pubitemid 41552526)
54. Han WK, Choi HK, Roth RM, et al. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003;63:1079-1085
55. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006;173:180-187
56. Sinico RA, Radice A, Corace C, et al. Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis. Ann NY Acad Sci 2005;1050:185-192 (Pubitemid 41129435)
57. Pradhan VD, Badakere SS, Pawar AR, et al. Anti-myeloperoxidase antibodies in patients with microscopic polyangiitis. Indian J Med Sci 2003;57:479-486